Pipeline
Robust Portfolio of New Drug Candidates

리스큐어는 독자적인 마이크로바이옴 기반 신약개발기술을 바탕으로 first-in-class and best-in-class 치료제 개발을 선도하고 있습니다.

R&D Pipeline
  • Indication
  • Product
  • Designations
  • Collaborators
  • Pre-clinical PoC
  • IND Enabling
  • Phase 1
  • Phase 2
  • Live
    Biotherapeutic Products

  • Primary Sclerosing Cholangitis

    MASH & MASLD

    Auto-immune Disease

    Parkinson’s Disease & Alzheimer’s Disease

    Parkinson’s Disease

    Parkinson’s Disease

    Solid Tumors

  • LB-P8

    LB-P8

    LB-P6

    LB-P4

    LB-PC01

    LB-PC02

    LB-P2L

  • ODD
    FTD

  • Bacterial immunotherapy

  • Solid Tumors
    (Advaned Cancers)

  • LB-P2D
  • Brain-targeted
    Drug Delivery
    System (DDS)
  • CNS Disorders
  • LB-P4E
Live Biotherapeutic Products
IndicationPrimary Sclerosing
Cholangitis
ProductLB-P8
Collaborators
IndicationMASH &
MASLD
ProductLB-P8
Collaborators
IndicationAuto-immune Disease
ProductLB-P6
Collaborators
IndicationParkinson & Alzheimer
ProductLB-P4
Collaborators
IND Enabling
IndicationParkinson
ProductLB-PC01
Collaborators
Pre-clinical PoC
IndicationParkinson
ProductLB-PC02
Collaborators
Pre-clinical PoC
IndicationSolid Tumors
ProductLB-P2L
Collaborators
Pre-clinical PoC
Bacterial immunotherapy
IndicationSolid Tumors
ProductLB-P2D
Collaborators
IND Enabling
Brain-targeted Drug Delivery System (DDS)
IndicationCNS Disorders
ProductLB-P4E
Collaborators
Pre-clinical PoC
  1. 01. Mayo Clinic과의 공동연구 (LB-P8 MASH)
  2. 02. Mayo Clinic과의 공동연구 (LB-P8 Rare Liver Diseases)
  3. 03. Celltrion과의 공동연구 (LB-PC01&PC02 Parkinson’s Disease)
  4. 04. Scripps Research와의 공동연구 (LB-P2D&P2L Immuno-Oncology)